Drugs / MK-1092
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03170544 | Aug 2017 → Nov 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1092 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03170544 ↗ |
| Modality | Protein / enzyme biologic | “MK-1092 is a synthetic insulin dimer with favorable properties demonstrated in preclinical studies.” PMID 35390172 ↗ May 2022 |
| Route | Subcutaneous | “MK-1092 subcutaneously (SC)” NCT03170544 ↗ |